Feb 28 |
Ventyx Biosciences GAAP EPS of -$0.79
|
Feb 27 |
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
|
Feb 26 |
Microcap ZyVersa up 71% on study supporting new way to fight obesity
|
Feb 23 |
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
|
Feb 22 |
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
|
Feb 21 |
Weight-Loss Drug Hype Sends Biotech Ventyx’s Stock Soaring on Rival’s Data
|
Feb 21 |
Ventyx surges as Piper highlights potential against obesity
|
Feb 6 |
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|